9,164 results match your criteria Annals Of Pharmacotherapy[Journal]


The Use of High-Dose Corticosteroids Versus Low-Dose Corticosteroids With and Without Tocilizumab in COVID-19 Acute Respiratory Distress Syndrome.

Ann Pharmacother 2022 May 19:10600280221094571. Epub 2022 May 19.

Division of Pulmonary Critical Care, NYU Langone Health, New York, NY, USA.

Background: Corticosteroids and tocilizumab have been shown to improve survival in patients who require supplemental oxygen from coronavirus disease 2019 (COVID-19) pneumonia. The optimal dose of immunosuppression for the treatment of COVID-19 acute respiratory distress syndrome (ARDS) is still unknown.

Objective: The objective of this study was to evaluate the effectiveness and safety of high- versus low-dose corticosteroids with or without tocilizumab for the treatment of COVID-19 ARDS. Read More

View Article and Full-Text PDF

Considerations When Using Body Mass Index as a Size Descriptor.

Ann Pharmacother 2022 May 19:10600280221097968. Epub 2022 May 19.

Department of Pharmacy Practice & Science, University of Arizona, R. Ken Coit College of Pharmacy, Tucson, AZ, USA.

View Article and Full-Text PDF

Abrocitinib: A New FDA-Approved Drug for Moderate-to-Severe Atopic Dermatitis.

Ann Pharmacother 2022 May 19:10600280221096713. Epub 2022 May 19.

Department of Dermatology, Center for Dermatology Research, Wake Forest School of Medicine, Winston-Salem, NC, USA.

Objective: The objective of this article is to review abrocitinib, an oral Janus kinase (JAK) 1 inhibitor, for the treatment of patients with moderate-to-severe atopic dermatitis (AD).

Data Sources: A literature search of MEDLINE (PubMed) was performed for articles from inception through end-March 2022 using the following search terms: atopic dermatitis, abrocitinib, PF-04965842, methotrexate, cyclosporine, dupilumab, ruxolitinib, and JAK-STAT pathway.

Study Selection And Data Extraction: English articles relating to pharmacology, pharmacokinetics, efficacy, and safety of abrocitinib, and other conventional systemic medications for AD, were included. Read More

View Article and Full-Text PDF

Comparison of Two-Bag Versus Three-Bag N-Acetylcysteine Regimens for Pediatric Acetaminophen Toxicity.

Ann Pharmacother 2022 May 19:10600280221097700. Epub 2022 May 19.

University of Colorado Anschutz Medical Campus, Aurora, CO, USA.

Background: Acetaminophen overdose is a leading cause of liver failure, and a leading cause of pediatric poisoning requiring hospital admission. The antidote, N-acetylcysteine (NAC), is traditionally administered as a three-bag intravenous infusion. Despite its efficacy, NAC is associated with high incidence of nonallergic anaphylactoid reactions (NAARs). Read More

View Article and Full-Text PDF

Successful Desensitization to Remdesivir Hypersensitivity in a Patient Undergoing Treatment for COVID-19.

Ann Pharmacother 2022 May 18:10600280221096883. Epub 2022 May 18.

Department of Allergy and Clinical Immunology, Chonnam National University Hospital, Chonnam National University Medical School, Gwangju, South Korea.

View Article and Full-Text PDF

Relationship Between Mean Arterial Pressure and Furosemide Stress Test Success Rates: A Retrospective Cohort Study.

Ann Pharmacother 2022 May 14:10600280221096466. Epub 2022 May 14.

Department of Pharmaceutical Care, University of Iowa Hospitals and Clinics, Acute Care Pharmacy, Iowa City, IA, USA.

Background: The furosemide stress test (FST) is a safe and easy assessment of renal tubular function. Other factors, such as mean arterial pressure (MAP), which may influence the success rates of the FST, have not been well defined.

Objective: To evaluate the relationship between MAP and success rates of the FST in critically ill patients. Read More

View Article and Full-Text PDF

Outcomes of a Undiluted, One-Bag Desensitization Protocol for Chemotherapeutic Agents.

Ann Pharmacother 2022 May 14:10600280221093594. Epub 2022 May 14.

Pharmacy Department, Hospital Universitario Lucus Augusti, Lugo, Spain.

Background: Hypersensitive reactions (HSRs) often require that the provoking medication be discontinued but chemotherapeutic drugs are often essential for the treatment of the disease. Rapid drug desensitization is a procedure that induces temporary tolerance to the drug allowing continuation of treatment in patients who have presented HSRs. Most of the desensitization protocols use 3 bags with sequential dilutions of the drug, which are infused in gradual steps. Read More

View Article and Full-Text PDF

Bupivacaine/meloxicam ER: A New Dual-acting Extended-Release Local Anesthetic for Opioid-Sparing Postoperative Pain Management.

Ann Pharmacother 2022 May 10:10600280221086639. Epub 2022 May 10.

Department of Clinical Sciences, Fred Wilson School of Pharmacy, High Point University, High Point, NC, USA.

Objective: To review data for bupivacaine/meloxicam extended-release (ER) solution for management of postoperative pain and opioid-sparing effects.

Data Sources: Literature search of PubMed (1946 to August 2021) and ProQuest (1946 to August 2021) was performed using the terms: Zynrelef, HTX-011, and "bupivacaine AND meloxicam." Additional information sources include ClinicalTrials. Read More

View Article and Full-Text PDF

Tezepelumab in the Treatment of Uncontrolled Severe Asthma.

Ann Pharmacother 2022 May 10:10600280221095540. Epub 2022 May 10.

Wayne State University, Eugene Applebaum College of Pharmacy and Health Sciences and Ascension St. John Hospital, Detroit, MI, USA.

Objective: To review the pharmacology, efficacy, and safety of subcutaneous tezepelumab in the treatment of severe uncontrolled asthma.

Data Sources: The PubMed database and ClinicalTrials.gov were searched using the following terms: , , , and . Read More

View Article and Full-Text PDF

Efficacy of Eravacycline Best Previously Available Therapy for Adults With Pneumonia Due to Difficult-to-Treat Resistant (DTR) .

Ann Pharmacother 2022 May 5:10600280221085551. Epub 2022 May 5.

College of Pharmacy, Roseman University of Health Sciences, Henderson, NV, USA.

Background: Multidrug-resistant remains challenging to treat. Although eravacycline has activity against this pathogen, there are no studies evaluating outcomes.

Objective: To assess the efficacy of eravacycline compared with best previously available therapy in adults with difficult-to-treat resistant (DTR) pneumonia. Read More

View Article and Full-Text PDF

Estimation of Kidney Function in Patients With Multiple Myeloma: Implications for Lenalidomide Dosing.

Ann Pharmacother 2022 May 5:10600280221087218. Epub 2022 May 5.

Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, CA, USA.

Background: Lenalidomide is an immunomodulatory drug used to treat multiple myeloma that requires renal dosing adjustment based on Cockcroft-Gault (CG). Various equations to estimate kidney function exist and pose a potential issue with lenalidomide dosing.

Objective: The objective of this analysis was to evaluate the impact of estimating kidney function in newly diagnosed multiple myeloma patients with CG, Modification of Diet in Renal Disease (MDRD), and Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) and their potential impact on lenalidomide dosing. Read More

View Article and Full-Text PDF

Management of Venous Thromboembolism in Morbid Obesity With Rivaroxaban or Warfarin.

Ann Pharmacother 2022 May 3:10600280221089008. Epub 2022 May 3.

Department of Pharmacy, Ascension St. John Hospital, Detroit, MI, USA.

Background: Rivaroxaban is a first-line option for the management of venous thromboembolism (VTE). However, limited data are available regarding its effectiveness in morbidly obese patients.

Objective: To evaluate rates of thrombosis and bleeding in morbidly obese patients receiving rivaroxaban or warfarin for VTE. Read More

View Article and Full-Text PDF

Criminal Action Against Drug Counterfeiters: Assessment of the FDA Office of Criminal Investigation Database 2016 Through 2021.

Authors:
C Michael White

Ann Pharmacother 2022 May 2:10600280221092482. Epub 2022 May 2.

University of Connecticut School of Pharmacy, Storrs, CT, USA.

Objective: The objective of this study was to describe law enforcement oversight of counterfeit drugs by the Food and Drug Administration (FDA) in the United States from 2016 through 2021.

Methods: The FDA Office of Criminal Investigation database with hyperlinked press releases of enforcement actions was used to identify legal action against drug counterfeiters. Incidences of counterfeit drugs sold via Internet, how often they were obtained without a prescription, the most prevalent counterfeit drugs, the countries where counterfeit operations occurred, and the scale of counterfeit operations were assessed. Read More

View Article and Full-Text PDF

Ibrexafungerp in the Treatment of Vulvovaginal Candidiasis.

Ann Pharmacother 2022 May 2:10600280221091301. Epub 2022 May 2.

Pharmacy Practice, University of Health Sciences and Pharmacy, St. Louis, MO, USA.

Objective: To review the pharmacology, efficacy, and safety of ibrexafungerp in the management of vulvovaginal candidiasis (VVC).

Data Sources: Literature was sought using PubMed (1966-February 2022) and EMBASE (1973-February 2022), and clinicaltrials.gov. Read More

View Article and Full-Text PDF

Comparison of Managing Factor Xa Inhibitor to Unfractionated Heparin Transitions by aPTT Versus a Treatment Guideline Utilizing Heparin Anti-Xa Levels.

Ann Pharmacother 2022 May 2:10600280221090211. Epub 2022 May 2.

Department of Pharmaceutical Services, Sanford USD Medical Center, Sioux Falls, SD, USA.

Background: There are inadequate data on the optimal strategy for transitioning factor Xa inhibitors (FXai; apixaban, rivaroxaban) to unfractionated heparin (UFH) infusions.

Objective: In patients transitioning from an FXai to an UFH infusion, this study compared the safety and efficacy of monitoring UFH infusions using an activated partial thromboplastin time (aPTT) titration scale versus utilizing an UFH-calibrated anti-Xa titration scale aided by a novel institutional guideline.

Methods: A retrospective cohort analysis was conducted on adult patients transitioning from an FXai to an UFH infusion at 2 medical centers from June 1, 2018, to November 1, 2020. Read More

View Article and Full-Text PDF

Two Years of the COVID-19 Pandemic: What Lessons Have We Learned?

Authors:
Shannon Inglet

Ann Pharmacother 2022 May 2:10600280221090590. Epub 2022 May 2.

Drug Information Service, Intermountain Healthcare, Taylorsville, UT, USA.

Two years ago, the World Health Organization declared a global pandemic after an outbreak of a novel coronavirus. Since then, unprecedented challenges have shaped a "new normal." As of early March 2022, more than 6 million lives have been lost globally to COVID-19. Read More

View Article and Full-Text PDF

Evaluation of Ceftazidime Use in the Neonatal Intensive Care Unit and Association With Cephalosporin-Resistant Gram-Negative Bacteria.

Ann Pharmacother 2022 Apr 29:10600280221088270. Epub 2022 Apr 29.

Department of Pharmacy: Clinical and Administrative Sciences, University of Oklahoma College of Pharmacy, Oklahoma City, OK, USA.

Background: Cefotaxime shortage in 2015 led to increased ceftazidime use in the neonatal intensive care unit (NICU).

Objective: The purpose was to explore whether ceftazidime increases risk for development of resistant gram-negative organisms.

Methods: Retrospective evaluation of NICU patients with cultures positive for , , species, or between January1, 2015 and August 31, 2020. Read More

View Article and Full-Text PDF

Effectiveness and Safety of Lower Dose of Rivaroxaban for Cancer-Related Venous Thromboembolism: A Retrospective Cohort Study.

Ann Pharmacother 2022 Apr 25:10600280221084418. Epub 2022 Apr 25.

Department of Pharmacy, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan.

Background: Primary and recurrent venous thromboembolism (VTE) commonly occur in patients with cancer. However, because of the National Health Insurance regulations, available dosage forms, and clinical conditions, the prescribed dose of rivaroxaban may not be consistent with its recommended dose.

Objective: To evaluate the 6-month recurrence rate of VTE and safety of rivaroxaban for patients with cancer. Read More

View Article and Full-Text PDF

Balanced Salt Solutions for Critically Ill Patients: Nonplused and Back to Basics.

Ann Pharmacother 2022 Apr 7:10600280221084380. Epub 2022 Apr 7.

Department of Pharmacy Practice & Science, College of Pharmacy, University of Arizona, Tucson, AZ, USA.

Objectives: The purpose of this article is to summarize the results of major randomized controlled trials (RCTs) comparing clinical outcomes of critically ill patients treated with normal saline (NS) or balanced salt solutions (BSSs), address discordant results of these studies, and provide direction for future investigations.

Data Sources: PubMed (2011 to January 2022) with bibliographies of retrieved articles searched for additional articles.

Study Selection And Data Extraction: RCTs comparing NS and BSSs in critically ill adult patients. Read More

View Article and Full-Text PDF

Adalimumab-Adbm: The First Interchangeable Biosimilar for the Treatment of Inflammatory Diseases.

Ann Pharmacother 2022 Apr 7:10600280221082196. Epub 2022 Apr 7.

Department of Pharmacy and Inflammatory Bowel Disease Center, University of Chicago Medicine, Chicago, IL, USA.

Objective: The objective of the study was to review the pharmacologic and clinical profile of adalimumab-adbm (BI 695501), the first interchangeable biosimilar for treatment of inflammatory diseases.

Data Sources: A PubMed search was conducted from inception to December 2021 using the keywords and . Information was also obtained from published abstracts and package inserts. Read More

View Article and Full-Text PDF

Valproate: Not All Boxed Warnings Are Created Equal.

Ann Pharmacother 2022 Apr 7:10600280221085991. Epub 2022 Apr 7.

College of Pharmacy, University of Michigan, Ann Arbor, MI, USA.

Objective: Valproate has undergone significant changes in labeling to the boxed warnings associated with it. This review will analyze evidence regarding the valproate-boxed warnings for teratogenicity, hepatotoxicity, and pancreatitis, with a particular emphasis on the fetal risk.

Data Sources: A review of Pubmed, Cochrane Central Register, Google Scholar, manufacturer websites, and product labeling was performed from 1963 to February 2022, using the following search terms: . Read More

View Article and Full-Text PDF

Why Is Oral Phenylephrine on the Market After Compelling Evidence of Its Ineffectiveness as a Decongestant?

Ann Pharmacother 2022 Mar 25:10600280221081526. Epub 2022 Mar 25.

Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, FL, USA.

Ineffective over-the-counter (OTC) drugs should be removed from the US market. Despite solid research showing that oral phenylephrine is ineffective as a decongestant, the US Food and Drug Administration has failed to respond to a 2015 citizen's petition to remove it from the OTC nasal decongestant monograph. Other examples of scientifically proven ineffective OTC medications include guaifenesin as an expectorant, dextromethorphan as a cough suppressant, and chlorpheniramine for cold symptoms. Read More

View Article and Full-Text PDF

Ceftaroline: Systematic Review of Clinical Uses and Emerging Drug Resistance.

Ann Pharmacother 2022 Mar 18:10600280221082326. Epub 2022 Mar 18.

Division of Infectious Diseases, Saint Louis University, Saint Louis, MO, USA.

Objective: To assess the success rates of off-label uses of ceftaroline for infections caused by methicillin-resistant (MRSA) and evaluate emerging ceftaroline resistance.

Data Sources: We queried PubMed/MEDLINE, with the search term "Ceftaroline." Articles were restricted to the English language and year of publication (January 1, 2009-January 31, 2022). Read More

View Article and Full-Text PDF

Retrospective Evaluation of Intrapleural Tissue Plasminogen Activator With or Without Dornase Alfa for the Treatment of Traumatic Retained Hemothorax: A 6-Year Experience.

Ann Pharmacother 2022 Feb 20:10600280221077383. Epub 2022 Feb 20.

Univeristy of Cincinnati James L. Winkle College of Pharmacy, Cincinnati, OH, USA.

Background: Intrapleural fibrinolytic instillation is second-line treatment for retained hemothorax. Dornase alfa (DNase) has demonstrated efficacy in parapneumonic effusion, but the lack of deoxyribonucleoproteins limits direct extrapolation to traumatic retained hemothorax treatment.

Objective: This study evaluated the effectiveness of intrapleural tissue plasminogen activator (tPA) with and without DNase in the treatment of retained traumatic hemothorax. Read More

View Article and Full-Text PDF
February 2022

Thrombocytopenia Associated With Teicoplanin Use: A Retrospective Observational Study.

Ann Pharmacother 2022 Feb 18:10600280221078123. Epub 2022 Feb 18.

Division of Infectious Diseases, Department of Medicine, Hamad Medical Corporation, Doha, Qatar.

Background: Contradictory studies reporting vast heterogeneity in the teicoplanin-induced thrombocytopenia (TIT) incidence exist.

Objective: To identify the incidence of TIT associated with teicoplanin dosing range (6-12 mg/kg/dose) and the risk factors of TIT.

Methods: This retrospective observational study included adult patients who received teicoplanin for ≥3 consecutive days over a period of 3. Read More

View Article and Full-Text PDF
February 2022